Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2025-12-26 @ 12:34 AM
Study NCT ID:
NCT04450160
Status:
UNKNOWN
Last Update Posted:
2020-06-29
First Post:
2020-06-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trial of AEO in New Glioblastoma (GBM)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005909', 'term': 'Glioblastoma'}, {'id': 'D012640', 'term': 'Seizures'}], 'ancestors': [{'id': 'D001254', 'term': 'Astrocytoma'}, {'id': 'D005910', 'term': 'Glioma'}, {'id': 'D018302', 'term': 'Neoplasms, Neuroepithelial'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D059039', 'term': 'Standard of Care'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D000077204', 'term': 'Temozolomide'}], 'ancestors': [{'id': 'D019984', 'term': 'Quality Indicators, Health Care'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D006298', 'term': 'Health Services Administration'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D003606', 'term': 'Dacarbazine'}, {'id': 'D014226', 'term': 'Triazenes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 80}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}, 'statusVerifiedDate': '2020-06', 'completionDateStruct': {'date': '2022-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-06-25', 'studyFirstSubmitDate': '2020-06-23', 'studyFirstSubmitQcDate': '2020-06-25', 'lastUpdatePostDateStruct': {'date': '2020-06-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-06-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival', 'timeFrame': '6 months', 'description': 'Measurement of Overall Survival'}, {'measure': 'Progression Free Survival-6', 'timeFrame': '6 months', 'description': 'Survival at 6 months'}], 'secondaryOutcomes': [{'measure': 'Seizures', 'timeFrame': '6 months', 'description': 'Time from randomization to first seizure'}, {'measure': 'Chalfont-National Hospital Seizure Severity', 'timeFrame': '6 months', 'description': 'Measure of Seizure Severity Ranging from a minimum of 1 to a maximum of 27 with higher score indicating worse outcome'}, {'measure': 'PROMIS-Cancer - Fatigue', 'timeFrame': '6 months', 'description': 'Measure of Fatigue Ranging from a minimum of 0 to a maximum of 95 with the higher score indicating worse outcome.'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Glioblastoma', 'Oxaloacetate', 'Seizures', 'Warburg'], 'conditions': ['Glioblastoma Multiforme']}, 'referencesModule': {'references': [{'pmid': '30349820', 'type': 'BACKGROUND', 'citation': 'Augur ZM, Doyle CM, Li M, Mukherjee P, Seyfried TN. Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma. Front Nutr. 2018 Oct 5;5:91. doi: 10.3389/fnut.2018.00091. eCollection 2018.'}, {'pmid': '22392507', 'type': 'BACKGROUND', 'citation': 'Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs. 2012 Dec;30(6):2226-35. doi: 10.1007/s10637-012-9799-5.'}, {'pmid': '12749815', 'type': 'BACKGROUND', 'citation': 'Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003 Jul 20;143(2):115-22. doi: 10.1016/s0378-4274(03)00114-0.'}]}, 'descriptionModule': {'briefSummary': 'This is a multicenter, Phase 2, Proof-of-concept study in subjects with newly diagnosed glioblastoma multiforme (GBM).\n\nAll subjects will receive standard of care therapy for the treatment of their GBM and any Anti-Epileptic Drug (AED) deemed necessary for their surgical resection of the GBM. Patients who are taking concomitant AEDs will be eligible for the study. Treatment with Anhydrous Enol-Oxaloacetate will be added to the Standard of Care.\n\nThis study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival.', 'detailedDescription': 'Currently, the multidisciplinary Standard of Care treatment for Glioblastoma multiforme includes maximal surgical resection of the tumor followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy.This study will treat newly diagnosed GBM patients by adding Anhydrous Enol-Oxaloacetate treatment to their current Standard of Care.\n\nIn the body, Anhydrous Enol-Oxaloacetate (AEO) converts into "Oxaloacetate", a metabolite important for many biochemical reactions in the body. On a cellular level, oxaloacetate treatment has been found to modify cancer metabolism in GBM cells, reversing the "Warburg Effect", reducing glycolysis and reducing lactate production. In animals, oxaloacetate treatment has increased survival and reduced tumor growth of implanted GBM tumors.\n\nIn other animal studies, oxaloacetate has also shown to have neuo-protective effects including positive effects on seizure development.\n\n.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* • Histopathologic diagnosis of glioblastoma multiforme\n\n * Standard of care maximal feasible surgical resection of the glioma\n * Post-operative pre-enrollment MRI-Note: measurable disease is not required\n * Concomitant anti-epileptic drugs\n * Hemoglobin \\>9 g/dL\n * Platelets \\>100,000/microliter (mcL)\n * \\<3.0 Upper Limit of Normal Range (ULN) for Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and/or Alkaline Phosphatase\n * \\<2.0 Upper Limit of Normal Range (ULN) for serum creatinine\n * Karnofsky performance status \\>70\n * Mentally competent to follow study procedures\n * Male and female patients of childbearing potential must agree to use a dual method of contraception (a highly effective method of contraception in conjunction with barrier contraception) consistently and correctly from the first dose of study drug until 90 days after the last dose of study drug\n * Able to answer questions on the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire\n * Subject is willing and able to give informed consent and to follow instructions as per the protocol\n\nExclusion Criteria:\n\n* • Concomitant treatment with carmustine wafers or tumor-treating electric fields (TTFields)\n\n * QT Interval corrected with the fridericia formula (QTcF) \\>480ms\n * Significant concurrent illness / disease\n * Predicted life expectancy \\< 6 months from date of randomization\n * Pregnancy\n * Enrollment in another clinical trial during the course of the study'}, 'identificationModule': {'nctId': 'NCT04450160', 'acronym': 'AEO', 'briefTitle': 'Trial of AEO in New Glioblastoma (GBM)', 'organization': {'class': 'INDUSTRY', 'fullName': 'MetVital, Inc.'}, 'officialTitle': 'A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme', 'orgStudyIdInfo': {'id': 'Terra-001-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Standard of Care', 'description': 'Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.', 'interventionNames': ['Other: Standard of Care']}, {'type': 'EXPERIMENTAL', 'label': 'AEO with Standard of Care', 'description': 'Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).', 'interventionNames': ['Drug: Anhydrous Enol-Oxaloacetate (AEO)', 'Other: Standard of Care']}], 'interventions': [{'name': 'Anhydrous Enol-Oxaloacetate (AEO)', 'type': 'DRUG', 'description': 'Oral supplementation with AEO along with the Standard of Care (Temozolomide)', 'armGroupLabels': ['AEO with Standard of Care']}, {'name': 'Standard of Care', 'type': 'OTHER', 'otherNames': ['Chemotherapy with Temozolomide'], 'description': 'Standard of Care Temozolomide', 'armGroupLabels': ['AEO with Standard of Care', 'Standard of Care']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Alan B Cash, MS', 'role': 'CONTACT', 'email': 'acash@MetVital.com', 'phone': '858-947-5722'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'MetVital, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}